Planet 13 Holdings (PLNH) Liabilities and Shareholders Equity (2021 - 2026)
Planet 13 Holdings (PLNH) posted quarterly Liabilities and Shareholders Equity of $146.9 million for Q1 2026, down 27.91% year-over-year from $203.8 million in Q1 2025, and down 3.52% quarter-over-quarter from $152.3 million in Q4 2025.
Planet 13 Holdings (PLNH) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends
Planet 13 Holdings (PLNH) has reported Liabilities and Shareholders Equity for 6 consecutive years, with $146.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity fell 27.91% year-over-year to $146.9 million; the TTM figure through Mar 2026 stood at $658.7 million (down 26.48% YoY), while the FY2025 annual figure was $152.3 million, down 26.34% from the prior year.
- Liabilities and Shareholders Equity slipped to $146.9 million in Q1 2026 per PLNH's latest filing, from $152.3 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $274.0 million in Q1 2022 and bottomed at $146.9 million in Q1 2026.
- Historically, Liabilities and Shareholders Equity has averaged $204.1 million across 5 years, with a median of $206.7 million in 2023.
- Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity plunged 38.46% — and 2024, when it soared 49.89%.
- Planet 13 Holdings' Liabilities and Shareholders Equity stood at $220.1 million in 2022, then tumbled by 31.04% to $151.7 million in 2023, then jumped by 36.24% to $206.7 million in 2024, then decreased by 26.34% to $152.3 million in 2025, then slipped by 3.52% to $146.9 million in 2026.
- Business Quant data shows PLNH's Liabilities and Shareholders Equity at $146.9 million in Q1 2026, $152.3 million in Q4 2025, and $158.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 6.18 Bn |
| 10 | Planet 13 Holdings | 52.64 Mn | 36.16 Mn | 12.32 Mn | 144.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 144.28 Mn |
| Mar 31, 2026 | 146.91 Mn |
| Dec 31, 2025 | 152.28 Mn |
| Sep 30, 2025 | 158.50 Mn |
| Jun 30, 2025 | 200.98 Mn |
| Mar 31, 2025 | 203.79 Mn |
| Dec 31, 2024 | 206.73 Mn |
| Sep 30, 2024 | 242.96 Mn |
| Jun 30, 2024 | 242.43 Mn |
| Mar 31, 2024 | 157.39 Mn |
| Dec 31, 2023 | 151.75 Mn |
| Sep 30, 2023 | 162.10 Mn |
| Jun 30, 2023 | 206.70 Mn |
| Mar 31, 2023 | 211.48 Mn |
| Dec 31, 2022 | 220.06 Mn |
| Sep 30, 2022 | 263.41 Mn |
| Jun 30, 2022 | 268.44 Mn |
| Mar 31, 2022 | 274.00 Mn |
| Dec 31, 2021 | 213.81 Mn |